Indeed, Pancreas Cancer Olaparib Ongoing (POLO) clinical trial has found that Poly ADP-ribose Polymerase inhibitor (PARPi) showed significant benefit in BRCA1/2 mutant PDAC patients [8]. This evidence concerns the gene BRCA1 and pancreatic neoplasm.